| Year |
Citation |
Score |
| 2021 |
Free RB, Cuoco CA, Xie B, Namkung Y, Prabhu VV, Willette BKA, Day MM, Sanchez-Soto M, Lane JR, Laporte SA, Shi L, Allen JE, Sibley DR. Pharmacological characterization of the imipridone anti-cancer drug ONC201 reveals a negative allosteric mechanism of action at the D dopamine receptor. Molecular Pharmacology. PMID 34353882 DOI: 10.1124/molpharm.121.000336 |
0.356 |
|
| 2020 |
Moritz AE, Bonifazi A, Guerrero AM, Kumar V, Free RB, Lane JR, Verma RK, Shi L, Newman AH, Sibley DR. Evidence for a stereoselective mechanism for bitopic activity by extended-length antagonists of the D3 dopamine receptor. Acs Chemical Neuroscience. PMID 32969645 DOI: 10.1021/acschemneuro.0c00425 |
0.362 |
|
| 2020 |
Schardien KA, Soto MS, Inbody L, Berchiche Y, Kehrl JH, Bradfield C, Free RB, Sibley DR. Investigation of G protein‐coupled receptor kinase 2 (GRK2) regulation of D
2
dopamine receptor signaling: effects of GRK2 functional domains and pharmacologic and genetic inhibition of GRK2 activity The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.05825 |
0.331 |
|
| 2020 |
Sanchez-Soto M, Schardien KA, Inbody L, Free RB, Sibley DR. G protein‐coupled receptor kinase 2 can enhance beta‐arrestin recruitment to the D
2
dopamine receptor in the absence of receptor phosphorylation The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.03478 |
0.366 |
|
| 2020 |
Moritz AE, Inbody LR, Gandhi DM, Akano E, Fearce C, Free RB, Barnaeva ES, Hu X, Southall NT, Ferrer M, Keck TM, Frankowski KJ, Sibley DR. Structure‐Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.02441 |
0.301 |
|
| 2019 |
Keck TM, Free RB, Day MM, Brown SL, Maddaluna MS, Fountain G, Cooper C, Fallon B, Holmes M, Stang C, Burkhardt R, Bonifazi A, Ellenberger MP, Newman AH, Sibley DR, et al. Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy. Journal of Medicinal Chemistry. PMID 30883109 DOI: 10.1021/Acs.Jmedchem.9B00231 |
0.343 |
|
| 2018 |
Luderman KD, Conroy JL, Free RB, Southall N, Ferrer M, Sanchez-Soto M, Moritz AE, Willette BKA, Fyfe TJ, Jain P, Titus S, Hazelwood LA, Aube J, Lane JR, Frankowski KJ, et al. Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites. Molecular Pharmacology. PMID 30068735 DOI: 10.1124/Mol.118.113175 |
0.343 |
|
| 2017 |
Madhukar N, Prabhu VV, Anantharaman L, Sulli C, Davidson E, Deacon S, Tarapore R, Rucker J, Charter N, Doranz B, Oster W, Elemento O, Free RB, Sibley D, Allen JE. EXTH-43. DIFFERENTIATED PHARMACOLOGY OF THE IMIPRIDONE ONC201, THE FIRST SELECTIVE DRD2/3 ANTAGONIST IN CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 19: vi81-vi82. DOI: 10.1093/Neuonc/Nox168.335 |
0.337 |
|
| 2015 |
Michino M, Free RB, Doyle TB, Sibley DR, Shi L. Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors. Chemical Communications (Cambridge, England). 51: 8618-21. PMID 25896577 DOI: 10.1039/C5Cc02204E |
0.356 |
|
| 2015 |
Meade JA, Free RB, Miller NR, Chun LS, Doyle TB, Moritz AE, Conroy JL, Watts VJ, Sibley DR. (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling. Psychopharmacology. 232: 917-30. PMID 25231919 DOI: 10.1007/S00213-014-3726-8 |
0.396 |
|
| 2014 |
Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD, Newman AH, Sibley DR. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 25583363 DOI: 10.1016/J.Euroneuro.2014.11.013 |
0.399 |
|
| 2013 |
Sibley DR, Free RB, Namkung Y, Lisa A. Sorting NEXIN-25 Interacts with D1 and D2Dopamine Receptors to Regulate Receptor Expression and Signaling Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 96-97. DOI: 10.1016/B978-0-12-800044-1.00083-0 |
0.37 |
|
| 2010 |
Rankin ML, Hazelwood LA, Free RB, Namkung Y, Rex EB, Roof RA, Sibley DR. Molecular Pharmacology of the Dopamine Receptors Dopamine Handbook. DOI: 10.1093/acprof:oso/9780195373035.003.0006 |
0.331 |
|
| 2010 |
Bergmeier SC, Lapinsky DJ, Free RB, McKay DB. ChemInform Abstract: Ring E Analogues of Methyllycaconitine (MLA) as Novel Nicotinic Antagonists. Cheminform. 30: no-no. DOI: 10.1002/chin.199946124 |
0.523 |
|
| 2007 |
Free RB, Hazelwood LA, Cabrera DM, Spalding HN, Namkung Y, Rankin ML, Sibley DR. D1 and D2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin. The Journal of Biological Chemistry. 282: 21285-300. PMID 17395585 DOI: 10.1074/Jbc.M701555200 |
0.333 |
|
| 2006 |
Free RB, Kaser DJ, Boyd RT, McKay DB. Receptor protection studies comparing recombinant and native nicotinic receptors: Evidence for a subpopulation of mecamylamine-sensitive native alpha3beta4* nicotinic receptors. Neuroscience Letters. 392: 135-9. PMID 16198480 DOI: 10.1016/J.Neulet.2005.09.002 |
0.793 |
|
| 2005 |
Free RB, McKay SB, Gottlieb PD, Boyd RT, McKay DB. Expression of native alpha3beta4* neuronal nicotinic receptors: binding and functional studies investigating turnover of surface and intracellular receptor populations. Molecular Pharmacology. 67: 2040-8. PMID 15772292 DOI: 10.1124/Mol.104.009282 |
0.755 |
|
| 2003 |
Free RB, von Fischer ND, Boyd RT, McKay DB. Pharmacological characterization of recombinant bovine alpha3beta4 neuronal nicotinic receptors stably expressed in HEK 293 cells. Neuroscience Letters. 343: 180-4. PMID 12770692 DOI: 10.1016/S0304-3940(03)00381-1 |
0.641 |
|
| 2003 |
Free RB, McKay DB. Surface and intracellular nicotinic receptors expressed in intact adrenal chromaffin cells: direct measurements using [3H]epibatidine. Brain Research. 974: 60-9. PMID 12742624 DOI: 10.1016/S0006-8993(03)02551-4 |
0.622 |
|
| 2002 |
McKay DB, Free RB, Kaser DJ, McKay SB. Characterization of [(3)H]epibatidine binding to nicotinic receptors from bovine adrenal medulla. Annals of the New York Academy of Sciences. 971: 162-4. PMID 12438112 DOI: 10.1111/J.1749-6632.2002.Tb04456.X |
0.753 |
|
| 2002 |
Free RB, McKay SB, Boyd RT, McKay DB. Evidence for constitutive expression of bovine adrenal a3beta4* nicotinic acetylcholine receptors. Annals of the New York Academy of Sciences. 971: 145-7. PMID 12438106 DOI: 10.1111/J.1749-6632.2002.Tb04450.X |
0.743 |
|
| 2002 |
Bryant DL, Free RB, Thomasy SM, Lapinsky DJ, Ismail KA, Arason KM, Bergmeier SC, McKay DB. Effects of methyllycaconitine and related analogues on bovine adrenal alpha3beta4* nicotinic acetylcholine receptors. Annals of the New York Academy of Sciences. 971: 139-41. PMID 12438104 DOI: 10.1111/J.1749-6632.2002.Tb04448.X |
0.777 |
|
| 2002 |
Bryant DL, Free RB, Thomasy SM, Lapinsky DJ, Ismail KA, McKay SB, Bergmeier SC, McKay DB. Structure-activity studies with ring E analogues of methyllycaconitine on bovine adrenal alpha3beta4* nicotinic receptors. Neuroscience Research. 42: 57-63. PMID 11814609 DOI: 10.1016/S0168-0102(01)00304-2 |
0.697 |
|
| 2002 |
Free RB, Bryant DL, McKay SB, Kaser DJ, McKay DB. [3H]Epibatidine binding to bovine adrenal medulla: evidence for alpha3beta4* nicotinic receptors. Neuroscience Letters. 318: 98-102. PMID 11796195 DOI: 10.1016/S0304-3940(01)02489-2 |
0.737 |
|
| 2001 |
Free RB, McKay DB. Receptor protection studies to characterize neuronal nicotinic receptors: tubocurarine prevents alkylation of adrenal nicotinic receptors. Brain Research. 891: 176-84. PMID 11164821 DOI: 10.1016/S0006-8993(00)03204-2 |
0.777 |
|
| 2000 |
Free RB, Wenger BW, McKay DB. Effects of sulfhydryl modification on adrenal nicotinic acetylcholine receptors: disulfide integrity is not essential for activation. Life Sciences. 68: 373-85. PMID 11205888 DOI: 10.1016/S0024-3205(00)00943-7 |
0.584 |
|
| 1999 |
Bergmeier SC, Lapinsky DJ, Free RB, McKay DB. Ring E analogs of methyllycaconitine (MLA) as novel nicotinic antagonists. Bioorganic & Medicinal Chemistry Letters. 9: 2263-6. PMID 10465558 DOI: 10.1016/S0960-894X(99)00378-9 |
0.734 |
|
| Show low-probability matches. |